Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Cytokine-induced killer (CIK) cells are a unique population of cytotoxic T lymphocytes (CTL) with the characteristic CD3+CD56+ phenotype. These cells have demonstrated higher proliferative and cytolytic activities in comparison to the reported CD3-CD56+ lymphokine activated killer (LAK) cells that are essentially activated natural killer (NK) cells. CIK cells are non-MHC-restricted in target cell recognition and killing. We have shown the feasibility of generating CIK cells from a series of marrow samples of patients with acute myeloid leukemia (AML) collected at diagnosis. At maturity, the CIK cells exhibit potent cytotoxicity against autologous AML targets as well as allogeneic myeloid leukemia cells, regardless of the HLA types of these targets. This observed cytotoxicity is not entirely due to NK cells as prior pre-absorption of the NK cells cytolytic activities does not abolish the subsequent cytotolytic activities against leukemic targets. It has also been reported by others that CIK cells are cytolytic against chronic myeloid leukemia (CML) cells, both in vitro and in the SCID mouse tumor model. In a mouse transplant model across MHC barrier, the CIK cells generated from the donor do not induce graft vs. host disease as observed for unfractionated donor splenocytes. In comparison to untreated control mice, the infusion of CIK cells results in the prolonged survival of murine leukemia-bearing mice. CIK cells also express CD94, part of the NK receptor comprising of CD94-NKG2 heterodimer. However, only low level of the killer immunoglobulin-like receptors are expressed by the CIK cells. In addition, as reported for the classical CTL, CIK cells could interact with dendritic cells (DC) to result in the enhancement of cytotolytic activities against tumor cells. The characteristic biological properties of the CIK cells would, therefore, enable them to be exploited for anti-leukemic therapy.
Linn
Y C
YC
Singapore General Hospital, Outram Road, Singapore and National Cancer Centre, Singapore.
Hui
Kam M
KM
D000818:Animals; D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D002478:Cells, Cultured / Q000187:drug effects / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D003602:Cytotoxicity, Immunologic; D005544:Forecasting; D006801:Humans; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000637:transplantation; D007938:Leukemia / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D051379:Mice; D016513:Mice, SCID; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation; D023041:Xenograft Model Antitumor Assays
D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2; D007371:Interferon-gamma